Ultragenyx Pharmaceutical Inc. (RARE)

Compare

33.84

-2.37

(-6.55%)

At close: April 1 at 4:00:00 PM EDT

34.29

+0.45

+(1.33%)

Pre-Market: 4:02:28 AM EDT

Why Ultragenyx Pharmaceutical (RARE) Is Among the Best Mid Cap Biotech Stocks to Buy

We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at where Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) stands against the other best mid cap biotech stocks to buy. Is the Biotech Sector Oversaturated? On March 6, Jared Holz, Mizuho health care […]

Insider Monkey 3 days ago

RARE
-6.55%
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 21,806 restricted stock units of the company’s common stock to 16 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Empl

GlobeNewswire 13 days ago

RARE
-6.55%
Ultragenyx price target lowered to $115 from $140 at Piper Sandler

Piper Sandler lowered the firm’s price target on Ultragenyx (RARE) to $115 from $140 and keeps an Overweight rating on the shares after analyst coverage transfer. The firm says that while this name boasts a strong commercial business, Piper notes a collection of high value, relatively low risk assets with appropriate balance across early, mid- and late-stage development. Several key clinical and regulatory catalysts are on tap, most near-term and top of mind being the second interim analysis of

TipRanks 14 days ago

RARE
-6.55%
Ultragenyx to Participate at Investor Conferences in March

NOVATO, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced participation in three upcoming investor conferences. 45th Annual Cowen Healthcare Conference (Boston, MA) Monday, March 3, 2025, Eric Crombez, M.D., Chief Medical Officer, will participate in a fireside chat and host 1x1 meetings. Barclays 2

GlobeNewswire last month

RARE
-6.55%
Exploring Three High Growth Tech Stocks in the United States

In the last week, the United States market has been flat, yet it has shown a robust 21% increase over the past year, with earnings expected to grow by 14% annually in the coming years. In this context of overall market growth and stability, identifying high growth tech stocks involves looking for companies with strong innovation potential and solid financial health that can capitalize on these favorable conditions.

Simply Wall St. last month

CMRX

RARE
-6.55%
MVIS
Ultragenyx Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)

FDA decision expected by August 18, 2025NOVATO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced the U.S. Food and Drug Administration (FDA or the Agency) has accepted for review the Biologics License Application (BLA) seeking accelerated approval for UX111 (ABO-102) AAV gene therapy as a treatment for patients with Sanfilippo syndrome type A (MPS IIIA). The FDA granted the BLA Priority Review with a Prescription Drug User Fee Act (PDUFA) ac

GlobeNewswire last month

RARE
-6.55%
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Last week, you might have seen that Ultragenyx Pharmaceutical Inc. ( NASDAQ:RARE ) released its yearly result to the...

Simply Wall St. last month

RARE
-6.55%
Q4 2024 Ultragenyx Pharmaceutical Inc Earnings Call

Q4 2024 Ultragenyx Pharmaceutical Inc Earnings Call

Thomson Reuters StreetEvents last month

RARE
-6.55%
Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y

RARE reports mixed fourth-quarter results, as earnings miss estimates while revenues beat the same. Product sales increase year over year.

Zacks last month

RARE
-6.55%
Ultragenyx Pharmaceutical Inc (RARE) Q4 2024 Earnings Call Highlights: Strong Revenue Growth ...

Ultragenyx Pharmaceutical Inc (RARE) reports a 29% revenue increase in 2024, driven by successful product launches and international expansion, despite a significant net loss.

GuruFocus.com last month

RARE
-6.55%
Ultragenyx: Q4 Earnings Snapshot

The average estimate of 10 analysts surveyed by Zacks Investment Research was for a loss of $1.24 per share. The biotechnology company posted revenue of $164.9 million in the period, which topped Street forecasts. Five analysts surveyed by Zacks expected $163.2 million.

Associated Press Finance last month

RARE
-6.55%
Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update

2024 Total Revenue of $560 million, exceeding guidanceCrysvita® revenue of $410 million and Dojolvi® revenue of $88 million 2025 Financial Guidance: Total Revenue between $640 million to $670 million, Crysvita revenue of $460 million to $480 million, and Dojolvi revenue of $90 million to $100 million NOVATO, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for s

GlobeNewswire last month

RARE
-6.55%
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update

NOVATO, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Thursday, February 13, 2025, to discuss its financial results and corporate update for the quarter and the year ending December 31, 2024. The live and replayed webcast of the call will be

GlobeNewswire last month

RARE
-6.55%
RARE Reports New Upbeat Data From Sanfilippo Syndrome Drug Study

Ultragenyx announces new safety and efficacy data from its pivotal study of its investigational candidate, UX111, for patients with Sanfilippo syndrome type A.

Zacks last month

RARE
-6.55%
Ultragenyx announces new data on UX111 AV gene therapy

Ultragenyx (RARE) Pharmaceutical announced new data demonstrating treatment with UX111 AAV gene therapy led to a statistically significant improvement in the Bayley-IIIi raw scores for the subdomains of cognition, receptive communication and expressive communication in patients with Sanfilippo syndrome type A compared to natural history data from untreated patients. These clinical endpoints were correlated with substantial and sustained reduction in levels of heparan sulfate in cerebrospinal flu

TipRanks last month

RARE
-6.55%
Ultragenyx Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome Type A (MPS IIIA) Correlated with Sustained Reductions in CSF-HS

Modified intent-to-treat group demonstrated +22.7 point (p<0.0001) treatment effect in the mean Bayley-III cognitive raw score compared to natural history data (ages 24-60 months) Older children with more advanced disease demonstrated retention of clinically meaningful functional abilities, including communication, ambulation and self-feeding The latest data from the pivotal Transpher A and long-term follow-up studies will be presented at WORLDSymposium™ 2025 NOVATO, Calif., Feb. 05, 2025 (GLOBE

GlobeNewswire last month

RARE
-6.55%
Why Ultragenyx Pharmaceutical (RARE) Is the Biotech Stock with the Biggest Upside Potential

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to take a look at where Ultragenyx Pharmaceutical, Inc. (NASDAQ:RARE) stands against other biotech stocks with the biggest upside potential. Improving Trends for Biotech Stocks While 2024 was a “challenging” year for biotech stocks, […]

Insider Monkey 2 months ago

RARE
-6.55%
Ultragenyx's Multiple Commercial Assets And Candidates Impress Analyst; Sees Solid Upside

In conjunction with the 2025 J.P. Morgan Healthcare Conference, the analyst hosted an investor lunch with Ultragenyx Pharmaceutical Inc (NASDAQ:RARE). The analyst keeps an Overweight rating on Ultragenyx with a price target of $102 and says the company is uniquely positioned in the long term with an expansive and diverse pipeline of orphan disease assets and highly regarded management. JP Morgan sees multiple value-creating catalysts over the next six to 18 months. Ultragenyx’s recent meeting fo

Benzinga 2 months ago

RARE
-6.55%
Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones

Preliminary 2024 total revenue of $555 million to $560 million, exceeding top end of guidance, including Crysvita® revenue of $405 million to $410 million, and Dojolvi® revenue of $87 million to $89 million 2025 expected total revenue guidance of $640 million to $670 millionUX143 (setrusumab) Phase 3 Orbit study for osteogenesis imperfecta progressing to second interim analysis in mid-2025 GTX-102 Phase 3 Aspire study for Angelman syndrome expected to complete enrollment in second half of 2025 N

GlobeNewswire 2 months ago

RARE
-6.55%
RARE's Cholesterol Drug Evkeeza Gains EC Approval for Expanded Use

EC expands the label of Ultragenyx's Evkeeza in the EU to treat younger patients aged 6 months to 5 years suffering from a rare cholesterol disorder.

Zacks 2 months ago

RARE
-6.55%

Performance Overview

Return	RARE	S&P 500 (^GSPC)
YTD	-19.56%	-4.23%
1-Year	-27.95%	+7.42%
3-Year	-56.26%	+23.92%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Ultragenyx Pharmaceutical Inc. (RARE)

Why Ultragenyx Pharmaceutical (RARE) Is Among the Best Mid Cap Biotech Stocks to Buy

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ultragenyx price target lowered to $115 from $140 at Piper Sandler

Ultragenyx to Participate at Investor Conferences in March

Exploring Three High Growth Tech Stocks in the United States

Ultragenyx Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Q4 2024 Ultragenyx Pharmaceutical Inc Earnings Call

Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y

Ultragenyx Pharmaceutical Inc (RARE) Q4 2024 Earnings Call Highlights: Strong Revenue Growth ...

Ultragenyx: Q4 Earnings Snapshot

Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update

RARE Reports New Upbeat Data From Sanfilippo Syndrome Drug Study

Ultragenyx announces new data on UX111 AV gene therapy

Ultragenyx Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome Type A (MPS IIIA) Correlated with Sustained Reductions in CSF-HS

Why Ultragenyx Pharmaceutical (RARE) Is the Biotech Stock with the Biggest Upside Potential

Ultragenyx's Multiple Commercial Assets And Candidates Impress Analyst; Sees Solid Upside

Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones

RARE's Cholesterol Drug Evkeeza Gains EC Approval for Expanded Use

Performance Overview